Your browser doesn't support javascript.
loading
The Abbreviated Methacholine Challenge Test is Safe for Children.
Hevroni, Avigdor; Nemet, Shay; Ringel, Amit; Boursheh, Laurice; Handler, Nitay Alter; Bar-Yishay, Ephraim.
Afiliação
  • Hevroni A; Department of Pediatrics and the Pediatric Pulmonology and CF Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Department of Pediatrics, Assuta Medical Center, Ashdod, Israel. Electronic address: Avigdor@hadassah.org.il.
  • Nemet S; Clinical Immunology Allergy and AIDS Center, Kaplan Medical Center, Rehovot, Israel.
  • Ringel A; Department of Pediatric Hemato-Oncology, Dana Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel.
  • Boursheh L; Department of Pediatrics and the Pediatric Pulmonology and CF Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • Handler NA; Clinical Immunology Allergy and AIDS Center, Kaplan Medical Center, Rehovot, Israel.
  • Bar-Yishay E; Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheba, Israel.
J Pediatr ; 276: 114250, 2024 Aug 22.
Article em En | MEDLINE | ID: mdl-39181318
ABSTRACT

OBJECTIVE:

To evaluate the safety of an abbreviated methacholine challenge test (MCT) protocol in children. STUDY

DESIGN:

This prospective, observational study enrolled children aged 6 through 18 years referred for the MCT. The abbreviated protocol was initiated with a methacholine dose of 0.03 mg/ml and escalated in fourfold increments, unless the forced expiratory volume at 1 second decline exceeded 10%, at which point the next dose was only doubled. The safety of this abbreviated approach was assessed by monitoring adverse events, and specifically, decreases in forced expiratory volume at 1 second over 40%, hypoxemia, or uncontrollable cough. The number of methacholine doses and test duration were recorded and compared with estimated outcomes derived from the full-length MCT protocol.

RESULTS:

One hundred twelve participants, aged 13.7 years (±3.3), successfully completed the protocol. Fifty-seven (51%) presented a positive MCT response. No significant clinical adverse events were observed. Of all participants, 2.7% exhibited an exaggerated response, in line with previously reported findings for the full-length protocol. The abbreviated approach resulted in an estimated average time-savings of 1819 minutes per participant, thus reducing test length by 2247 minutes for a negative MCT and by 1434 minutes for a positive outcome.

CONCLUSIONS:

This abbreviated MCT protocol is safe for children and effectively shortens the duration of the MCT.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Pediatr Ano de publicação: 2024 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Pediatr Ano de publicação: 2024 Tipo de documento: Article País de publicação: Estados Unidos